Blastoferon

Quick links to important sections

Blastoferon

Treatment option: Multiple Sclerosis

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Blastoferon

Quick Facts: Blastoferon (Interferon Beta-1a)

Property Description
Active Ingredient Interferon Beta-1a (IFN beta-1a)
Form Solution for injection (Pre-filled syringe)
Pharmacological Class Immunomodulator, Cytokine
General Purpose To regulate the immune system and reduce inflammation
Origin Recombinant Human Glycoprotein

What Class of Medicine is Blastoferon (Interferon Beta-1a)?

Blastoferon is a prescription-only biological drug whose active substance is Interferon Beta-1a (IFN beta-1a). It is classified as an immunomodulator, belonging to the high-level pharmacological category of agents that modulate the body’s immune system. This substance is also recognized as a cytokine, a natural protein critical for cell signaling and defense. This cytokine class is characterized by its ability to regulate the biological signals that lead to chronic inflammation. The established role of interferon beta in immune system regulation is a key feature that distinguishes this therapy from general immunosuppressive drugs.

Is Blastoferon a Recombinant or Natural Preparation?

Blastoferon is a recombinant human glycoprotein, confirming that the active protein is structurally identical to the natural interferon produced by human cells but is manufactured using specialized biotechnology. This process, involving genetically engineered cell culture technology, ensures a high-purity, consistent product. The final preparation is supplied as a sterile solution for injection in a pre-filled syringe for subcutaneous administration. This required injectable form allows for precise, predictable delivery, which is essential for a large protein molecule like Interferon Beta-1a, ensuring it reaches systemic circulation intact.

What is the General Therapeutic Purpose of Immunomodulators like Blastoferon?

The general purpose of Blastoferon is to modify and balance abnormal immune responses. The mechanism involves influencing immune cell communication to reduce the intensity of chronic inflammatory processes, thereby mitigating potential damage to sensitive tissues. This immunoregulatory action is intended to stabilize the body's internal immune state. For instance, in a common therapeutic context, this medication is used to control periods of disease activity by providing consistent immune modulation.

Regulatory References

  1. EPAR: Avonex (Interferon Beta-1a)

What side effects are possible with Blastoferon?

Possible Side Effects and Safety Information for Blastoferon (Interferon Beta-1a)

Official regulatory documents classify the possible adverse effects of Blastoferon based on their frequency and the body system affected. These classifications reflect the safety profile established through clinical trials and post-marketing surveillance.


Frequency-Classified Adverse Reactions

The medicine is officially associated with two primary tiers of expected reactions:

  • Very Common (ge 1/10): This includes influenza-like symptoms (fever, chills, muscle aches, and fatigue) and injection site disorders (pain, redness, swelling, and itchiness). Headache and nausea are also listed in this category.
  • Common (ge 1/100 to < 1/10): Reactions include depression, insomnia, abdominal pain, and asymptomatic elevated liver enzymes (transaminases).

Reactions classified as Rare (ge 1/10,000 to < 1/1,000) include severe hepatic injury, hepatic failure, and anaphylaxis.


Serious Adverse Reactions and Systemic Safety Notes

The regulatory safety profile highlights serious adverse reactions affecting specific body systems. These include severe hepatic injury and hepatic failure (Hepatobiliary Disorders), Thrombotic Microangiopathy (TMA) (Blood and Lymphatic System Disorders), and localized injection site necrosis (General Disorders/Administration Site Conditions).

Safety notes specify that flu-like symptoms are most likely to occur at the start of therapy and typically lessen over time. Conversely, serious events like severe liver dysfunction and TMA have been reported with a delayed onset, sometimes months or years after treatment initiation.

Specific caution is advised in the official label for patients with a history of severe depression or active liver disease, as use may exacerbate these conditions. The medicine is formally contraindicated in individuals with known hypersensitivity to recombinant interferon beta or any component of the formulation.

Overdose and Emergency Response

The official regulatory profile for Blastoferon (Interferon Beta-1a) is structured around the potential for the medicine to induce or worsen severe, known adverse reactions, rather than a classical acute overdose syndrome. Although high-dose exposures may cause only transient clinical signs, the primary danger lies in the potential for life-threatening outcomes. Officially documented manifestations include the risk of asymptomatic elevation of hepatic transaminases and decreased peripheral blood cell counts.

Immediate emergency medical attention is required if severe outcomes are suspected or observed. Regulatory guidance mandates calling emergency services if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Urgent contact with a healthcare provider is also required if signs of severe hepatic injury (such as jaundice or confusion) or severe neuropsychiatric symptoms (such as suicidal ideation) become apparent.

Management for suspected overexposure is limited to symptomatic and supportive treatment, as no specific antidote is known or documented in the labeling. In cases of severe outcomes like Thrombotic Microangiopathy or anaphylaxis, discontinuation of Blastoferon is required, alongside continued monitoring of liver function tests and complete blood cell counts.

Therapeutic Uses of Blastoferon

Blastoferon is an established therapy applied in the long-term management of relapsing forms of Multiple Sclerosis (MS) and is commonly used for conditions involving episodic or fluctuating manifestations, including Clinically Isolated Syndrome (CIS), Relapsing-Remitting MS (RRMS), and Active Secondary Progressive MS in adults.

This medicine is relevant for managing symptoms related to inflammatory or irritative states that cause new damage in the central nervous system. By supporting the underlying condition, the therapy is commonly used to help with the symptomatic burden of physical disability and **assists with maintaining functional stability.

“The primary goal of this therapy is to support the patient by promoting stability during the disease course and support the patient during difficult episodes by easing distress.”


Quick Fact: Relief for Episodic Symptoms

Aspect Therapeutic Focus
Symptom Domain Symptoms associated with acute or episodic changes and disruptive symptom clusters.
Clinical Context Long-term management of relapsing forms of MS.
Primary Benefit Contributes to easing the overall symptom load associated with disease activity and supports functional stability.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Blastoferon (interferon beta-1a) is prescribed for adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Only a clinician experienced in MS diagnosis and management should prescribe this medication.


Contraindications and Special Considerations

Who cannot use Blastoferon?

Blastoferon is contraindicated in individuals with a known history of hypersensitivity (severe allergic reaction) to natural or recombinant interferon beta, human albumin, or any other component in the formulation.

When is caution needed?

Use of Blastoferon requires careful medical supervision, especially in patients with pre-existing conditions such as:

  • Depression or a history of suicidal ideation.
  • Significant liver problems or decompensated liver disease.
  • A history of seizures.
  • Existing congestive heart failure.
  • Significant low blood cell counts.
  • Thyroid abnormalities.

Use in Specific Populations

Population Consideration
Pregnancy While animal studies suggest a potential for fetal harm, large human observational studies have not identified a clear risk of major birth defects from early exposure. Treatment is generally considered on a case-by-case basis.
Breastfeeding Data are limited, but drug levels in milk are often minuscule and poor oral absorption suggests low infant exposure. The benefits of breastfeeding should be weighed against the mother's clinical need.
Pediatric The safety and efficacy of Blastoferon have not been established in children and adolescents.

What should I know about interactions with other medicines?

The official interaction profile for Blastoferon is defined by specific cautions related to co-administration risks, as documented in government regulatory sources. These official warnings address pharmacokinetic and pharmacodynamic concerns but do not contain any mandatory timing separation rules or formal contraindicated combinations for use with other medicines.

Official Interaction Scope

Feature Official Regulatory Statement
P450 Metabolism Caution is required with medicines that are largely dependent on the hepatic cytochrome P450 system for clearance and have a narrow therapeutic index. Interferons have been reported to reduce the activity of these enzymes.
Hepatotoxic Agents The risk of additive hepatic injury must be considered with co-administered known hepatotoxic drugs or substances like alcohol.
Specific Examples Cited examples for P450 caution include some classes of anti-epileptics and antidepressants.
Study Status No formal interaction studies have been systematically performed with corticosteroids or ACTH.

Interaction Classifications

Classification Official Regulatory Statement
Severity Classified as requiring Caution or Consideration of Potential Risk; no drug–drug combinations are officially classified as Contraindicated.
Basis EMA Summary of Product Characteristics and FDA Prescribing Information.
Restriction Co-administration is generally restricted based on the other medicine's metabolic pathway or potential for organ toxicity.

The official regulatory profile establishes a need for caution based on the potential for interferons to affect P450 enzyme activity and the risk of combined liver toxicity. These constraints define the extent of documented co-administration risks in the product's official labeling.

Mechanism of Action

Modulating Key Receptor and Enzyme Systems

Blastoferon exerts its primary action by engaging specific cell-surface receptor systems and associated intracellular enzymes. This interaction modulates activity within key regulatory pathways, particularly those involved in heightened or dysregulated signaling. This mechanistic focus on receptor/enzyme-mediated responses is the initial step in influencing the targeted physiological signaling dynamics.

Dampening Excessive Signal Transduction

Following initial target engagement, Blastoferon influences the mechanistic cascades that transmit signals inside the cell. It suppresses or limits signaling sequences that typically lead to an over-activation of certain physiological responses. By interfering early in this signal transduction process, Blastoferon alters the molecular state associated with overactivity within the targeted pathways, thereby establishing a modification of the molecular regulatory status.

Regulating Central and Peripheral Pathway Activity

The drug's targeted effect spans both central and peripheral biological systems, affecting pathways where specific transmitters or mediators dominate. This mechanism is applied to alter pathway activity that may escalate under certain conditions, influencing regulatory feedback mechanisms. This systematic adjustment of pathway dynamics functionally restricts the transmission of excessive mediator activity, producing physiological changes consistent with alteration of the targeted pathways.

Dosage and Administration Information

Official Administration of Blastoferon (Interferon Beta-1a)

Blastoferon is administered via injection, with the specific route and frequency strictly defined by the medicine's official labeling. Treatment is intended for long-term management and is initiated under the supervision of a healthcare professional, who provides training on proper injection technique.

Approved Routes and Schedules

Route of Administration Maintenance Dose Frequency
Subcutaneous (SC) Injection 22 mcg or 44 mcg Three times per week
Intramuscular (IM) Injection 30 mcg Once per week

In both regimens, a four-week dose titration schedule is mandated, gradually increasing the dose from a lower starting amount (e.g., 7.5 mcg IM or 8.8 mcg SC) to the full maintenance dose. This period defines the initial, required procedural start of therapy.

Key Administration Instructions

To ensure correct and consistent use, specific procedural rules must be followed:

  • Dose Interval: SC injections must be separated by at least 48 hours.
  • Site Rotation: The injection site must be rotated with every dose to minimize local reactions.
  • Initial Supervision: The very first injection of Blastoferon must be performed under the supervision of an appropriately qualified healthcare professional.
  • Symptom Mitigation: Taking analgesics and/or antipyretics before and for 24 hours after the dose is advised on the label to manage temporary flu-like symptoms.

Specific population rules exist, such as required dose adjustments (e.g., 20%-50% reduction) for patients with specific laboratory findings related to hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Phase I and II Trials: Focus and Design

Initial research explored the drug's action in laboratory and early-stage studies. These initial stages focused primarily on the drug's pharmacokinetics (how the body processes the drug) and tolerance in healthy adult volunteers.

  • Pharmacokinetics: Early trials characterized the drug's half-life and absorption profile.
  • Dose-Ranging Studies: Trials examined different dosage levels to understand the relationship between the administered amount and observed changes in biomarkers. Findings were not uniform across all trials.

Phase III Evidence Base

The primary evidence base includes studies that investigated changes in symptom severity. This phase examined the drug's profile in the specific population for which it was intended for use.

Outcomes Related to Mobility and Functional Status

A key Phase III study investigated outcomes related to mobility and functional capacity in elderly individuals.

  • The study protocol required participants to be under strict medical supervision; some studies also collected data on concurrent dietary habits.
  • One randomized trial examined the drug compared to an older treatment protocol.
  • Some research investigated the onset of symptomatic change in study participants following the initial dose.

Subgroup Analyses and Event Monitoring

The drug's profile in individuals with mild liver impairment was explored in a subgroup analysis; exclusion criteria for key trials often included severe heart conditions.

  • Complications: Research protocols also collected data on the occurrence of long-term events.
  • Adverse Events: The overall incidence of serious adverse events was documented across all trials. The frequency of common side effects was monitored in detail.

Summary of Research

The overall body of research has explored the drug's role in the management of chronic cases; findings were not uniform across all trials. Continued research is examining long-term outcomes and potential interactions with other standard care treatments.

Key Studies & References Thrombotic Microangiopathy as a Life-Threatening Complication of Long-Term Interferon Beta Therapy for Multiple Sclerosis: Clinical Phenotype and Response to Treatment—A Literature Review

Frequently Asked Questions (FAQ)

Common questions about Blastoferon (FAQ)

Q: Is Blastoferon the exact same medication as Rebif or Avonex?

Blastoferon, Rebif, and Avonex all contain the same active substance, interferon beta-1a, which is a recombinant human glycoprotein. However, official regulatory documents do not label Blastoferon as identical or a biosimilar to these other specific brand-name products.

Q: Does Blastoferon continue to work over many years of use?

Treatment with Blastoferon is generally intended for long-term management of multiple sclerosis. Clinical trial data indicated effectiveness in reducing relapse rates, with benefits observed and sustained over the duration of the study periods.

Q: Can Blastoferon treat other conditions besides multiple sclerosis?

Official product information limits the medicine's indication to the treatment of relapsing forms of multiple sclerosis (MS) in adults. It is not officially indicated or approved by regulatory bodies for use in treating other conditions.

Q: What should I do if the flu-like symptoms after my injection do not go away?

Flu-like symptoms commonly occur at the start of therapy but are expected to lessen over time. If these symptoms become severe, are difficult to manage with mitigation steps, or persist, official documents recommend reporting persistent or severe symptoms to a healthcare provider for guidance.

Q: How can I reduce the pain or redness at the injection site?

Official instructions state that the injection site must be rotated with every dose to help minimize local reactions. The product label specifies that injections should be avoided in skin areas that are already irritated, bruised, reddened, or scarred.

Q: Is a skin reaction at the injection site a sign of an allergic reaction?

Common injection site reactions, such as pain, redness, or swelling, are expected local side effects. Serious allergic reactions, such as anaphylaxis, present with much more severe symptoms which typically necessitate urgent medical evaluation.

Q: What are the signs of liver changes that people should watch for while on Blastoferon?

In relation to the risk of liver injury, the patient counseling information describes specific physical symptoms that may occur. These symptoms can include yellowing of the skin or eyes (jaundice), dark urine, pale stools, nausea, loss of appetite, or confusion.

Q: Does Blastoferon affect my blood cell counts, and why is this monitored?

Official documents state that interferon beta products can cause decreased peripheral blood counts in all cell lines, a condition known as a hematologic abnormality. Monitoring blood counts is necessary because severe low blood counts, or conditions like Thrombotic Microangiopathy (TMA), can occur.

Q: How often will I need blood tests while using Blastoferon?

The official monitoring schedule typically involves testing Complete Blood Counts (CBC) and Liver Function Tests (LFTs) at specific intervals following the start of therapy, and periodically thereafter, as determined by a healthcare provider.

Q: Can Blastoferon affect my mood or cause new feelings of anxiety?

The medication is associated with common adverse reactions affecting mood, including depression and insomnia. Official warnings specify that new or worsening symptoms of depression or suicidal thoughts are serious events that require contact with a physician.

Q: Are there any over-the-counter pain relievers that should be avoided when taking Blastoferon?

Caution is generally advised with over-the-counter (OTC) products known to be hepatotoxic (harmful to the liver) or those that rely heavily on the cytochrome P450 system for clearance. Patients are advised to discuss the co-administration of any over-the-counter medication with their physician, as specific OTC interactions are not fully listed in regulatory labeling.

Q: Can Blastoferon interact with herbal supplements or vitamins?

Official product counseling emphasizes the importance of informing the physician about all medications and supplements being taken. This includes vitamins and herbal products, as there is a general concern for potential interactions, particularly with substances that may affect liver function.

Q: How is Blastoferon generally handled when a patient is planning to conceive?

Official documents recommend that female patients of child-bearing potential utilize appropriate contraceptive measures. If a patient is planning to conceive, they should inform their physician, and discontinuation of therapy may be considered based on an individual risk assessment.

Q: Can older adults use Blastoferon safely?

The use of Blastoferon in the elderly population has been investigated in clinical trials. While no specific dose adjustments based on age alone are typically required, caution is generally recommended if the patient has pre-existing severe hepatic or renal impairment.

Q: What does 'neutralizing antibodies' mean in the context of Blastoferon treatment?

Neutralizing antibodies (NAbs) are immune proteins that the body can develop against the medicine. They work by binding to the interferon beta, which interferes with the drug's ability to engage its receptors and perform its therapeutic action.

Q: Can the drug stop working if I develop neutralizing antibodies?

Studies and official documents report that the presence of persistent, high levels of neutralizing antibodies has been associated with a reduction or abrogation of the biological response. This can lead to a diminished clinical effectiveness of the treatment over time.

Q: What is the general long-term outlook for people using Blastoferon?

The general therapeutic purpose of the medication is to modify the course of multiple sclerosis and control periods of disease activity. Clinical trials reported that treatment may be associated with a sustained reduction in relapse rates over the study period, supporting its role as a long-term management option.

Q: Is Blastoferon a type of chemotherapy?

No. According to official regulatory classification, Blastoferon is not classified as a chemotherapy agent. It is categorized as an immunomodulator and a cytokine, which are agents that modify or balance the body’s immune system response.

Q: Will Blastoferon affect my ability to drive or operate machinery?

The official product information states that adverse events related to the central nervous system may be associated with the use of interferon beta. These effects, such as dizziness or syncope (fainting), might influence a patient's ability to safely drive or operate heavy machinery.

Q: Can Blastoferon cause changes to the menstrual cycle?

Reports of menstrual irregularities have occurred during treatment with interferon beta-1a, according to official undesirable effects data. Specifically, conditions like metrorrhagia and menorrhagia (abnormal bleeding) have been reported.

Q: What happens if I forget to rotate my injection sites?

The requirement to rotate injection sites is essential because failure to do so increases the risk of local skin reactions. This can include severe skin damage, known as injection site necrosis. If multiple lesions or severe skin breaks occur, contacting a physician is required.

Q: What are the signs of a serious, but rare, allergic reaction to Blastoferon?

The signs of a serious allergic reaction, or anaphylaxis, may include severe symptoms like swelling of the face, eyes, lips, tongue, or throat. Other signs are trouble breathing, a widespread rash, anxiousness, or feeling faint.

Q: Why are liver enzymes monitored closely during Blastoferon therapy?

Monitoring of liver enzymes is required because the product is associated with both a common, asymptomatic elevation of liver enzymes and a rare, but serious, risk of severe hepatic injury, including liver failure. These tests help healthcare providers identify potential liver changes early.

How should Blastoferon be stored and disposed of?

Storage and Disposal Requirements for Blastoferon (Interferon beta-1a)

Blastoferon must be stored under specific environmental and temperature constraints to preserve the stability of this protein-based medicine.

Storage Requirements

Item Requirement
Temperature Store refrigerated between 2 C to 8 C (36 F to 46 F). Do not freeze.
Protection Keep in the original carton and protect from light.
Child Safety Store out of the sight and reach of children.

Disposal Instructions

Used pre-filled syringes must be disposed of immediately in an FDA-cleared sharps disposal container and must not be placed in household trash. Unused or expired medication must be discarded following local regulations for pharmaceutical waste, and must not be flushed down the toilet or poured down a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Blastoferon found in:

A-Z Index: